MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-10-2022
Oyster Point Pharma Total Inventories 2011-2026 | OYST
Annual Total Inventories Oyster Point Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 6.09 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 6.09 M | 6.09 M | 6.09 M |
Quarterly Total Inventories Oyster Point Pharma
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 6.96 M | 6.64 M | 4.09 M | 6.09 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 6.96 M | 4.09 M | 5.95 M |
Total Inventories of other stocks in the Biotechnology industry
| Issuer | Total Inventories | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amphastar Pharmaceuticals
AMPH
|
177 M | $ 19.44 | -0.46 % | $ 909 M |  USA |
 |
Albireo Pharma
ALBO
|
194 K | - | -0.23 % | $ 916 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
6.71 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acorda Therapeutics
ACOR
|
16.2 M | - | -24.86 % | $ 820 K | USA |
 |
Tarsus Pharmaceuticals
TARS
|
4.37 M | $ 67.0 | -0.3 % | $ 2.8 B | USA |
 |
bluebird bio
BLUE
|
22.9 M | - | - | $ 546 M | USA |
 |
Theravance Biopharma
TBPH
|
16.8 M | $ 14.9 | -1.91 % | $ 750 M |  Cayman-islands |
 |
Avid Bioservices
CDMO
|
30.4 M | - | - | $ 789 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
4.14 M | $ 1.2 | -6.97 % | $ 306 M |  Britain |
 |
BeiGene, Ltd.
BGNE
|
608 M | - | 0.49 % | $ 251 B | Cayman-islands |
 |
Bio-Techne Corporation
TECH
|
189 M | $ 51.31 | -2.65 % | $ 8.08 B | USA |
 |
Tenax Therapeutics
TENX
|
99.2 K | $ 14.64 | -2.2 % | $ 574 M | USA |
 |
BioDelivery Sciences International
BDSI
|
23.7 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
2.82 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
851 K | - | - | $ 3.74 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
3.18 B | $ 28.76 | -3.43 % | $ 32.9 B |  Israel |
 |
Eton Pharmaceuticals
ETON
|
15.4 M | $ 23.81 | 1.51 % | $ 641 M | USA |